---
title: "CVN636 acts as a selective positive allosteric modulator at mGlu7/7 homodimers"
id: "biorxiv-17-cvn636-potentiates-orthosteric-agonist-responses-selectively-at-mglu7-7"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-17-cvn636-potentiates-orthosteric-agonist-responses-selectively-at-mglu7-7"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.10.17.759826v1?rss=1"
published_at: "2026-10-19T10:27:13.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# CVN636 acts as a selective positive allosteric modulator at mGlu7/7 homodimers
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-17-cvn636-potentiates-orthosteric-agonist-responses-selectively-at-mglu7-7
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.10.17.759826v1?rss=1)
- **Published At:** 2026-10-19T10:27:13.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study used complementary bioluminescence resonance energy transfer (BRET)–based assays to measure both downstream signaling and G protein recruitment; investigators reported these assays as the primary experimental tools. - Authors observed that **CVN636** did not activate **mGlu7** on its own in their BRET systems; the molecule failed to produce receptor signaling in the absence of an orthosteric agonist. - Instead, data indicated **CVN636** behaved as a positive allosteric modulator (PAM), increasing the potency and efficacy of orthosteric agonist responses in an agonist-dependent manner. - A competitive orthosteric antagonist abolished CVN636 activity, consistent with a mechanism requiring orthosteric agonist binding rather than direct agonism. - Using an assay capable of resolving signaling from defined receptor dimers, the study team observed that CVN636 activity was selective for **mGlu7/7** homodimers. - Investigators tested mGlu7-containing heterodimers and found no potentiation by CVN636 at those heteromeric assemblies in the assay system. - The authors noted prior reports described CVN636 as an allosteric agonist with in vivo efficacy in a rodent alcohol use disorder model; the present data indicate that the compound’s effects may instead stem from **mGlu7/7** homodimer PAM activity. - The report is a preprint and has not been peer reviewed; the authors did not report specific dosing regimens, quantitative effect sizes, or detailed in vivo methodology in this abstract, and those details would need to be confirmed in the full manuscript or subsequent peer-reviewed publications.
## Clinical Analysis & Structured Key Points
CVN636 potentiates orthosteric agonist responses selectively at mGlu7/7 homodimers | bioRxiv Skip to main content New Results CVN636 potentiates orthosteric agonist responses selectively at mGlu 7/7 homodimers View ORCID Profile Xin Lin , View ORCID Profile Colleen M. Niswender , View ORCID Profile Wesley B. Asher , View ORCID Profile Jonathan A. Javitch doi: https://doi.org/10.64898/2026.10.17.759826 Xin Lin 1 Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Xin Lin Colleen M. Niswender 2 3.Department of Pharmacology, Warren Center for Neuroscience Drug Discovery, Vanderbilt Brain Institute, Vanderbilt Institute of Chemical Biology, Vanderbilt Institute for Translational Advances, Vanderbilt University, Nashville, TN 37232, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Colleen M. Niswender Wesley B. Asher 1 Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Wesley B. Asher Jonathan A. Javitch 1 Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York, NY 10032, USA; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Jonathan A. Javitch For correspondence: jonathan.javitch{at}nyspi.columbia.edu Abstract Info/History Metrics Supplementary material Preview PDF Abstract The metabotropic glutamate receptor 7 (mGlu 7 ) is an emerging therapeutic target for central nervous system disorders, but progress has been limited by a lack of selective pharmacological tools. CVN636 was recently reported as a potent and selective allosteric agonist of this receptor, capable of receptor activation in the absence of glutamate, with demonstrated efficacy in a rodent model of alcohol use disorder. Here, using complementary bioluminescence resonance energy transfer–based assays that measure both downstream signaling and G protein recruitment, we show that CVN636 does not activate the receptor on its own. Instead, CVN636 acts as a positive allosteric modulator that enhances the potency and efficacy of orthosteric agonist responses, including those of glutamate, in an agonist–dependent manner. Blockade of orthosteric agonist binding with a competitive antagonist abolished CVN636 activity, consistent with this mechanism. Furthermore, using an assay that distinguishes signaling from defined receptor dimers, we find that CVN636 activity is selective for mGlu 7/7 homodimers and does not extend to any mGlu 7 –containing heterodimer tested. Thus, in our assay system CVN636 is an mGlu 7/7 homodimer–selective positive allosteric modulator of this receptor, suggesting that its in vivo actions likely stem from action at these homomers. Competing Interest Statement The authors have declared no competing interest. Funder Information Declared National Institute of Neurological Disorders and Stroke, https://ror.org/01s5ya894 , R01-NS132060 St. Jude Children's Research Hospital, https://ror.org/02r3e0967 , STCRH CU23-4900 Hope for Depression Research Foundation , 1019030 Miriam’s Magical Memorial Mission Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted October 19, 2026. Download PDF Supplementary Material Email Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following CVN636 potentiates orthosteric agonist responses selectively at mGlu7/7 homodimers Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share CVN636 potentiates orthosteric agonist responses selectively at mGlu 7/7 homodimers Xin Lin , Colleen M. Niswender , Wesley B. Asher , Jonathan A. Javitch bioRxiv 2026.10.17.759826; doi: https://doi.org/10.64898/2026.10.17.759826 Share This Article: Copy Citation Tools CVN636 potentiates orthosteric agonist responses selectively at mGlu 7/7 homodimers Xin Lin , Colleen M. Niswender , Wesley B. Asher , Jonathan A. Javitch bioRxiv 2026.10.17.759826; doi: https://doi.org/10.64898/2026.10.17.759826 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Animal Behavior and Cognition (8156) Biochemistry (19002) Bioengineering (15138) Bioinformatics (45171) Biophysics (22928) Cancer Biology (20046) Cell Biology (27240) Clinical Trials (138) Developmental Biology (14117) Ecology (21352) Epidemiology (2067) Evolutionary Biology (25747) Genetics (16308) Genomics (23785) Immunology (18974) Microbiology (43109) Molecular Biology (18289) Neuroscience (94837) Paleontology (711) Pathology (3024) Pharmacology and Toxicology (5174) Physiology (8255) Plant Biology (16226) Scientific Communication and Education (2113) Synthetic Biology (4630) Systems Biology (10363) Zoology (2418)
## Related Clinical Research

- [Spousal Health Effects After Major Diagnoses: Evidence from a US Matched Event Study](https://medichelpline.com/clinical-feed/pubmed-42496175.md) (DOI: 10.1093/aje/kwag178)
- [Early-Onset Metabolic Diseases Linked to Higher Depression, Stress, and Suicidality in a Nationwid](https://medichelpline.com/clinical-feed/pubmed-42773492.md) (DOI: 10.3349/ymj.2025.0342)
- [Whole-Brain Activation Patterns After Mu Opioid and NOP Receptor Agonism Reveal Regional and Netwo](https://medichelpline.com/clinical-feed/biorxiv-4-whole-brain-cellular-activation-after-mu-and-nop-receptor-agonism-identifies.md)
- [Tobacco use among Lebanese university students: prevalence, drivers, and campus policy implications](https://medichelpline.com/clinical-feed/plos-one-4-prevalence-and-determinants-of-tobacco-use-among-university-students-in-lebanon.md)
- [Midlife hearing decline and health links in the Busselton Healthy Ageing Study](https://medichelpline.com/clinical-feed/plos-one-14-change-in-hearing-loss-and-its-association-with-general-health-in-a-community.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.